From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, DORAVIRINE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, RALTEGRAVIR POTASSIUM
CABOTEGRAVIR · General benefit
1 Indications
VOCABRIA (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a
complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection
in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and
suppressed (HIV-1 RNA less than 50 copies/mL) as:
• an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA
• oral bridging therapy for missed CABENUVA injections
CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated:
• as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of
age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients
who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL).
1.1 Pediatrics
Pediatrics (≥ 12 and < 18 years of age): the use of VOCABRIA and CABENUVA in adolescent patients 12
years of age and older and weighing at least 35 kg is supported by the interim safety and
pharmacokinetic data of an ongoing phase 1/2 open-label, non-comparative study in which oral and
injectable cabotegravir or oral and injectable rilpivirine, each as a single agent, was administered in
combination with other antiretroviral agents, and also by the pharmacokinetic data from studies with
VOCABRIA, CABENUVA and oral and injectable rilpivirine use in adults (see 8.2.1 Clinical Trial Adverse
Reactions-Pediatrics, 10.3 Pharmacokinetics, and 14 CLINICAL TRIALS; oral rilpivirine use refers to the
EDURANT product monograph).
PM: https://pdf.hres.ca/dpd_pm/00080949.PDF; date 2025-06-30; DIN 02497204; fetched 2026-09-10
Product monograph
CABOTEGRAVIR & RILPIVIRINE · General benefit
1 Indications
VOCABRIA (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a
complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection
in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and
suppressed (HIV-1 RNA less than 50 copies/mL) as:
• an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA
• oral bridging therapy for missed CABENUVA injections
CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated:
• as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of
age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients
who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL).
1.1 Pediatrics
Pediatrics (≥ 12 and < 18 years of age): the use of VOCABRIA and CABENUVA in adolescent patients 12
years of age and older and weighing at least 35 kg is supported by the interim safety and
pharmacokinetic data of an ongoing phase 1/2 open-label, non-comparative study in which oral and
injectable cabotegravir or oral and injectable rilpivirine, each as a single agent, was administered in
combination with other antiretroviral agents, and also by the pharmacokinetic data from studies with
VOCABRIA, CABENUVA and oral and injectable rilpivirine use in adults (see 8.2.1 Clinical Trial Adverse
Reactions-Pediatrics, 10.3 Pharmacokinetics, and 14 CLINICAL TRIALS; oral rilpivirine use refers to the
EDURANT product monograph).
PM: https://pdf.hres.ca/dpd_pm/00080951.PDF; date 2025-06-30; DIN 02497220; fetched 2026-09-10
Product monograph
DARUNAVIR · Listed, not a benefit (2), General benefit (6)
1 INDICATIONS
Auro-Darunavir (darunavir), co-administered with 100 mg ritonavir, and with other
antiretroviral agents, is indicated for the treatment of HIV-1 infection in patients ≥ 40 kg.
PM: https://pdf.hres.ca/dpd_pm/00073833.PDF; date December 7, 2023; DIN 02486121; fetched 2026-09-10
Product monograph
DORAVIRINE · General benefit
1 Indications
PIFELTRO® (doravirine) is indicated, in combination with other antiretroviral medicinal products, for the
treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older and weighing at
least 35kg without past or present evidence of viral resistance to doravirine.
1.1 Pediatrics
Pediatrics ( 12 to < 18 years of age): The safety and efficacy of PIFELTRO® in pediatric patients 12
years of age and weighing at least 35 kg receiving doravirine 100 mg once daily has been established
(see 8.2.1 Clinical Trial Adverse Reactions – Pediatrics and 14 Clinical Trials).
PM: https://pdf.hres.ca/dpd_pm/00081853.PDF; date not captured; DIN 02481545; fetched 2026-09-10
Product monograph
EFAVIRENZ · Listed, not a benefit (1), General benefit (4)
INDICATIONS AND CLINICAL USE
Mylan-Efavirenz (efavirenz) is indicated for the treatment of HIV-1 infection in combination
with other antiretroviral agents.
PM: https://pdf.hres.ca/dpd_pm/00076879.PDF; date AUG 29, 2024; DIN 02381524; fetched 2026-09-10
Product monograph
EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE · General benefit
INDICATIONS AND CLINICAL USE
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR (efavirenz [EFV]/emtricitabine
[FTC]/tenofovir disoproxil fumarate [TDF]) is indicated for use alone as a complete regimen or
in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
PM: https://pdf.hres.ca/dpd_pm/00056758.PDF; date June 1, 2020; DIN 02393549; fetched 2026-09-10
Product monograph
EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE · General benefit
INDICATIONS AND CLINICAL USE
Treatment of HIV-1 Infection
TRUVADA is indicated in combination with other antiretroviral agents (such as non-
nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of HIV-1
infection in adults.
PM: https://pdf.hres.ca/dpd_pm/00046237.PDF; date July 5, 2018; DIN 02274906; fetched 2026-09-10
Product monograph
NEVIRAPINE · Listed, not a benefit (2), General benefit (5)
INDICATIONS AND CLINICAL USE
AURO-NEVIRAPINE (nevirapine) is indicated as an alternative for:
treatment of HIV-1 infection in combination with other antiretroviral agents.
PM: https://pdf.hres.ca/dpd_pm/00058912.PDF; date not captured; DIN 02318601; fetched 2026-09-10
Product monograph
RALTEGRAVIR POTASSIUM · General benefit
1 INDICATIONS
Adults
ISENTRESS® and ISENTRESS HD® (raltegravir) are indicated in combination with other antiretroviral
agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients.
1.1 Pediatrics
Pediatrics (2 - 18 years of age and weighing at least 7kg):
ISENTRESS® is indicated in combination with other antiretroviral agents for the treatment of HIV-1
infection in children and adolescents 2 years of age and older with body weight at least 7 kg.
PM: https://pdf.hres.ca/dpd_pm/00073112.PDF; date November 9, 2007; DIN 02301881; fetched 2026-09-10
Product monograph
TENOFOVIR DISOPROXIL · Limited Use, codes 517, 518, 519, 520, 521, 522
INDICATIONS AND CLINICAL USE
HIV-1 Infection
VIREAD (tenofovir disoproxil fumarate [TDF]) is indicated for the treatment of HIV-1
infection in combination with other antiretroviral agents in patients 12 years of age and older.
PM: https://pdf.hres.ca/dpd_pm/00045932.PDF; date June 13, 2018; DIN 02247128; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26